← Back to Search

Liquid Embolic System

Middle Meningeal Artery Embolization for Subdural Hematoma (EMBOLISE Trial)

Cleveland, OH
N/A
Waitlist Available
Led By Jason Davies, MD
Research Sponsored by Medtronic Neurovascular Clinical Affairs
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Pre-morbid Modified Rankin Score ≤3
Confirmed diagnosis of subacute or chronic subdural hematoma
Must not have
Contraindicated for the use of Onyx™ LES
Cannot be taken off corticosteroids (intended to treat subacute or chronic SDH) for at least 90 days post-randomization
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether a new medical treatment, embolization of the middle meningeal artery, is safe and effective for treating people with a type of brain bleed called a subdural hematoma.

See full description
Who is the study for?
This trial is for individuals with a confirmed diagnosis of subacute or chronic subdural hematoma, who are relatively independent in daily activities (Modified Rankin Score ≤3), and can consent to treatment. Excluded are those with life expectancy <1 year, severe symptoms (Markwalder score ≥ 3), active COVID-19, pregnancy, acute SDH, uncontrolled bleeding disorders, suspected infections within the brain, unsafe anatomy for the procedure, tumors or mass lesions in the brain, contraindications to angiography or Onyx™ LES use.Check my eligibility
What is being tested?
The study tests if blocking blood flow to the affected area using Onyx™ Liquid Embolic System through embolization of middle meningeal artery is safe and effective for treating symptomatic subacute/chronic subdural hematomas compared to no treatment or standard surgical management.See study design
What are the potential side effects?
Potential side effects may include complications from embolization such as inflammation around the treated area, allergic reactions to materials used like Onyx™ LES during embolization procedure; risks associated with angiography; and general risks related to invasive procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I was mostly independent in daily activities before my current illness.
 show original
Select...
I have been diagnosed with a long-lasting blood clot on the brain.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot use Onyx™ LES due to health reasons.
 show original
Select...
I must stay on corticosteroids for my SDH for at least 90 days after starting the trial.
 show original
Select...
I do not have any uncontrolled bleeding disorders.
 show original
Select...
I currently have an active COVID-19 infection.
 show original
Select...
I might have an infection in my blood or a secondary infection.
 show original
Select...
I have a brain tumor or mass seen on CT or MRI, and cannot undergo angiography.
 show original
Select...
I have been diagnosed with acute subdural hematoma.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Surgery Cohort: Treatment ArmExperimental Treatment1 Intervention
Treatment
Group II: Observational Cohort: Treatment ArmExperimental Treatment1 Intervention
Treatment
Group III: Surgery Cohort: Control ArmActive Control1 Intervention
Control
Group IV: Observational Cohort: Control ArmActive Control1 Intervention
Control
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Treatment
2013
Completed Phase 2
~10240

Find a Location

Closest Location:Oklahoma University Medical Center· Oklahoma City, OK· 159 miles

Who is running the clinical trial?

Medtronic Neurovascular Clinical AffairsLead Sponsor
31 Previous Clinical Trials
9,374 Total Patients Enrolled
Jason Davies, MDPrincipal InvestigatorBuffalo General Medical Center
Jared Knopman, MDPrincipal InvestigatorNew York-Presbyterian Hospital/Weill Cornell Medical Center
1 Previous Clinical Trials
6 Total Patients Enrolled

Media Library

Onyx™ Liquid Embolic System (Liquid Embolic System) Clinical Trial Eligibility Overview. Trial Name: NCT04402632 — N/A
Subdural Hematoma Research Study Groups: Surgery Cohort: Treatment Arm, Surgery Cohort: Control Arm, Observational Cohort: Treatment Arm, Observational Cohort: Control Arm
Subdural Hematoma Clinical Trial 2023: Onyx™ Liquid Embolic System Highlights & Side Effects. Trial Name: NCT04402632 — N/A
Onyx™ Liquid Embolic System (Liquid Embolic System) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04402632 — N/A
~112 spots leftby Mar 2026